Navigation Links
Vermillion Announces Stockholder Approval of Reverse Stock Split
Date:2/15/2008

- Board of Directors Approve a 1 for 10 Reverse Split

FREMONT, Calif., Feb. 15 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRML), a high-value molecular diagnostics company, announced today that its stockholders authorized Vermillion's Board of Directors to implement a reverse split of the company's common stock. The Board of Directors has approved a 1 for 10 reverse stock split of the company's common stock. The reverse split is expected to become effective at the close of business on Monday, March 3, 2008.

"We believe this stockholder approval and reverse stock split will help attract a greater level of interest among investors and analysts. It comes at an excellent time given the advances being made in the clinical and commercial development of our peripheral arterial disease (PAD) and ovarian cancer diagnostics programs," said Gail S. Page, President and CEO of Vermillion.

In the reverse split, each ten (10) shares of Vermillion's issued and outstanding common stock will be combined into one (1) share of common stock. No fractional shares will be issued in association with the reverse stock split and holders of fractional shares will receive cash in place of their fractional shares.

Based on the volume and price of shares of the Company's common stock as of February 14, 2008, as a result of the reverse split, Vermillion will have approximately 6.4 million shares outstanding of its common stock. Additionally the reverse split will affect all shares of Vermillion's common stock, including underlying stock options outstanding and warrants immediately prior to the effective date of the reverse split.

Vermillion's transfer agent, Wells Fargo Shareowner Services will send instructions to stockholders of record regarding the exchange of certificates for common stock.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has ongoing diagnostic programs in oncology, hematology, cardiology and women's health with an initial focus in ovarian cancer. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at http://www.vermillion.com.

Forward Looking Statements

This news release contains forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion's plans, objectives, expectations and intentions and the risks and uncertainties discussed in Vermillion's latest Form 10-K and Vermillion's periodic reports on Form 10-Q and Form 8-K. These forward-looking statements are based on Vermillion's current expectations. Vermillion is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise. Forward-looking statements cannot be guaranteed and actual results may differ materially from Vermillion's current expectations. You are encouraged to read Vermillion's reports filed with the U.S. Securities and Exchange Commission, available at http://www.sec.gov.


'/>"/>
SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Vermillion, Inc. Announces Receipt of Notice of Noncompliance From Nasdaq
2. Vermillion to Host Teleconference and Webcast to Discuss Third Quarter 2007 Financial Results on November 12 at 4:30 pm Eastern Time
3. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
4. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
5. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
6. HEI, Inc. Announces Sale of RFID Division Assets
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
9. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
10. Brooke Franchise Corporation Announces Selected July Results
11. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... , ... June 28, 2017 , ... ... is pleased to announce that a two year study conducted by the University ... Creek zeolite was successful in remediating potash brine-impacted groundwater. As a part of ...
(Date:6/28/2017)... VA (PRWEB) , ... June 28, 2017 , ... ... protection assistance and financial consultations to communities in northern Virginia and DC, is ... to help provide for patients with Alzheimer’s and other disorders that lead to ...
(Date:6/27/2017)... ... June 27, 2017 , ... Nearly 70 percent of ... released today by the American Society for Dermatologic Surgery (ASDS). , ... of consumers considering a cosmetic medical procedure has doubled since 2013. , “Cosmetic ...
(Date:6/27/2017)... ... June 27, 2017 , ... Salucro, the ... the health care industry’s hospitals and provider groups, has announced that it will ... customers. Parasail Health is a San Francisco health-finance startup that has launched a ...
(Date:6/27/2017)... ... ... From June 20-22, EarQ and Widex held an exclusive training ... EarQ is headquartered. , Together, the organizations educate hearing care professionals on how ... the latest in hearing technology. At the event, EarQ members got an in-depth ...
Breaking Medicine News(10 mins):
(Date:6/5/2017)... , June 5, 2017 Kohll,s Pharmacy ... the United States . The Raizer is ... a fallen person up to an almost-standing position ... and operated by one assistant and does not ... is simple enough that a child can operate it, ...
(Date:6/1/2017)... 2017 Nutriceutical Holdings (NH), parent company of ... and KD Pharma Group have decided to join forces ... Pharma Group. KD Pharma Group will become the largest ... the entire company. "We believe we have ... to growing the NH companies by providing us with ...
(Date:5/30/2017)... May 30, 2017 Therapix Biosciences Ltd. (Nasdaq: ... in the development of cannabinoid-based drugs, today announced ... overview at three upcoming scientific and investor conferences ... Micro Invitational: ... Date:                     Wednesday, ...
Breaking Medicine Technology: